Related Experiment Video
Updated: Oct 20, 2025
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
Discovery of novel BTK PROTACs for B-Cell lymphomas
Yunpeng Zhao1, Yongzhi Shu2, Jun Lin3
1Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China.
Abstract:
Bruton's tyrosine kinase (BTK) is a key drug target for B-cell related malignancies. Irreversible covalent BTK inhibitors have been approved for the treatment of B-cell malignancies, yet BTK C481S mutation at the covalent binding site has caused drug-resistance of BTK covalent binding inhibitors. The proteolysis targeting chimera (PROTAC) technology increases the sensitivity to drug-resistant targets compared to classic inhibitors, which provides a new strategy for mutant BTK related B-cell malignancies. ARQ531, a reversible non-covalent BTK inhibitor that inhibits wild type (WT) and mutated BTK with high selectivity, could be an ideal warhead for PROTACs targeting the mutant BTK. Herein, we designed a novel series of PROTACs using the selective non-covalent BTK inhibitor ARQ531 as warhead, with the goal of improving the degradation of both wild-type and C481S mutant BTKs, and increasing the selectivity of BTK over other kinases. This effort will provide some basis for further preclinical study of BTK PROTACs as a novel strategy for treatment of B-cell lymphomas.
Insights
New proteolysis targeting chimera (PROTAC) technology offers a promising strategy for B-cell malignancies resistant to covalent Bruton's tyrosine kinase (BTK) inhibitors. PROTACs utilizing ARQ531 show potential for degrading both wild-type and mutant BTK.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Bruton's tyrosine kinase (BTK) is a critical target for B-cell malignancies.
- Irreversible covalent BTK inhibitors face resistance due to the BTK C481S mutation.
- Proteolysis targeting chimera (PROTAC) technology presents a novel strategy for drug-resistant targets.
Purpose of the Study:
- To design novel PROTACs using the selective non-covalent BTK inhibitor ARQ531.
- To enhance the degradation of wild-type and C481S mutant BTKs.
- To improve BTK selectivity over other kinases for B-cell lymphoma treatment.
Main Methods:
- Design of novel PROTACs employing ARQ531 as the warhead.
- Utilizing PROTAC technology to target BTK and its mutations.
- Focusing on improving degradation efficiency and kinase selectivity.
Main Results:
- Development of a new series of PROTACs targeting BTK.
- Potential for improved degradation of both wild-type and mutant BTK.
- Aiming for enhanced selectivity of BTK inhibition.
Conclusions:
- Novel BTK-targeting PROTACs were designed using ARQ531.
- These PROTACs offer a potential strategy against drug-resistant B-cell malignancies.
- Further preclinical studies are warranted for BTK PROTACs in B-cell lymphomas.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
